Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus–infected patients with congenital coagulation disorders

Sauleda, Sílvia

doi:10.1053/jhep.2001.29130

Cited by 83 publications

(48 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, psychiatric disorders are of special concern, because of their potential severity and the high rate of treatment discontinuation. No deaths, life-threatening complications such as lactic acidosis and pancreatitis, [6][7][8]16 or new or unexpected adverse events were seen. In addition, a high rate of liver decompensation in the course of treatment was reported in coinfected patients with histologically proven cirrhosis.…”

Section: Discussionmentioning

confidence: 96%

“…4 In addition to the well-recognized adverse events, the increased risk of severe lactic acidosis, pancreatitis, and hepatic decompensation in the course of treatment with concomitant antiretroviral therapy is of special concern. [6][7][8] The real extent of this problem is unknown, but certain risk factors have been identified, such as treatment with didanosine. 8,9 In mid-2001, the encouraging results obtained in non-HIV patients 10,11 prompted us to implement treatment of CHC in HIV-coinfected patients with a combination of peg-INF and ribavirin in our hospital and associated centers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients

Santín

Shaw²,

García³

et al. 2006

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients

Santín

Shaw²,

García³

et al. 2006

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

“…8 We chose the 400 mg bid fixed dose of RBV because of concern for potential deleterious interactions when concomitantly taking some antiretroviral drugs (i.e., anemia with AZT, or pancreatitis with ddI). [17][18][19][20][21][22] It should be noted, however, that less than one-third of our study population received less than 10.6 mg/kg of RBV, and that no significant differences were noticed when comparing the response rate achieved in those with or without RBV exposure above 10.6 mg/kg.…”

Section: Pérez-olmeda Et Al 1086 Table 3 Negative Serum Hcv-rna Accmentioning

confidence: 61%

“…[15][16][17][18] Herein, we report the final results of a multicenter trial in which two different doses of IFN-a plus RBV were prescribed to a large group of not severely immunosuppressed HIV-positive individuals with chronic hepatitis C, all naive for IFN-a.…”

Section: Introduction Hmentioning

confidence: 99%

Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α-2b Plus Ribavirin

Pérez‐Olmeda

Soriano

Asensi

et al. 2003

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

One hundred six HIV-infected patients with chronic hepatitis C virus (HCV) infection were randomized to receive ribavirin (RBV) 400 mg bid plus interferon a-2b (IFN-a) at two different doses, 3 mU tiw (control arm) or 5 mU daily for the first 6 weeks, followed by 3 mU tiw until completing 6 months of therapy (induction arm). All patients had CD4 counts above 350 cells/ml and 89% were taking antiretroviral therapy. Adverse effects leading to treatment discontinuation occurred in 12.3% of patients, a rate quite similar to that seen in HCV-monoinfected patients. Negative serum HCV-RNA values (,60 IU/ml) were recorded in 24.7% and 35.5% of patients at 3 and 6 months of therapy. However, in the intent-to-treat analysis, sustained response was reached by only 16% of patients (22.4% in the on-treatment analysis). No differences between treatment arms were noticed. Patients with HCV genotypes 2 or 3 had a 7-fold higher response rate than those with HCV genotypes 1 or 4. Therefore, early, end-of-treatment, and sustained response rates are lower in HIV/HCV-coinfected patients treated with RBV/IFN-a combination therapy. Since HCV-related liver disease is currently one of the leading causes of morbidity and mortality among HIV-infected patients, new treatment options are urgently needed for coinfected individuals.

show abstract

“…is an antiviral agent used in combination with a-2b interferon to treat hepatitis C (25)(26)(27). Although this therapy is effective against hepatitis C virus, it has several side effects (28,29).…”

Section: Lobucavirmentioning

confidence: 99%

Biocatalytic Synthesis of Chiral Pharmaceutical Intermediates

Patel

2005

ChemInform

View full text Add to dashboard Cite

SummaryThe production of single enantiomers of drug intermediates has become increasingly important in the pharmaceutical industry. Chiral intermediates and fine chemicals are in high demand from both the pharmaceutical and agrochemical industries for the preparation of bulk drug substances and agricultural products. The enormous potential of microorganisms and enzymes for the transformation of synthetic chemicals with high chemo-, regio-and enantioselectivities has been demonstrated. In this article, biocatalytic processes are described for the synthesis of chiral pharmaceutical intermediates.

show abstract

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus–infected patients with congenital coagulation disorders

Cited by 83 publications

References 24 publications

Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients

Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients

Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α-2b Plus Ribavirin

Biocatalytic Synthesis of Chiral Pharmaceutical Intermediates

Contact Info

Product

Resources

About